The latest developments in the Regeneron v Kymab dispute.
Insights: Biotechnology & Pharmaceuticals
The UK Court of Appeal has reversed Mr Justice Carr’s finding in the High Court that Regeneron’s patent EP1360287, and its divisional EP2264163, were insufficient.
Regeneron v Kymab – Part II: Interpretation and Infringement
An agreement allowing European patents to be validated for Cambodia entered into force on 1 March 2018.
Tom Bosworth highlights a recent case warning potential SPC applicants to apply for and obtain marketing authorisation promptly.
Rose Hughes considers a recent UK Court of Appeal case on the patent doctrine of “obvious to try” in the context of clinical trials.
The prestigious European Medicine Agency (EMA) is to relocate from London to Amsterdam following a decision by EU foreign affairs ministers.
Andrew Carridge takes another look at the concept of plausibility in European patent applications and the possible implications for your patent strategy.